Evaluation study on dementia Berlin-Brandenburg (VDBB) Epidemiological investigation on the impact of diagnosis, based on biomarker criteria, onto the treatment strategy on patients with cognitive impairment, in the sense of knowledge generating medicine.

Evaluation study on dementia Berlin-Brandenburg (VDBB) Epidemiological investigation on the impact of diagnosis, based on biomarker criteria, onto the treatment strategy on patients with cognitive impairment, in the sense of knowledge generating medicine. - VDBB-02

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011375

Enrollment

Registered

2017-05-30

Start date

2017-06-29

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F06.7 F00

Interventions

Group 1: The participating patients will be examined within the standard care setting of the S3-guideline for dementia. The diagnostics will be conducted in accordance with clinical criteria (neuropsy

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: 1. Adults age = 75 2.Patients with mild cognitive impairment (MCI) or mild dementia (MMST = 20 points or DemTect = 9 points) with suspicion of Alzheimer's (Hachinski test < 4 points) 3.According to guidelines with biomarkers continuative diagnostics is recommended by the examining physician. 4.The patient is voluntarily taking part in the study and has given his written permission for the use of his pseudonymized patient data.

Exclusion criteria

Exclusion criteria: 1. Previous amyloid PET scan with available investigating results. 2. Simultaneous participating in a clinical trial on disease-modifying treatments for Alzheimer's 3.Severe depression (GDS > 10 points) 4.The occurrence of a neurological disorder, frequently associated with dementia, e.g. Parkinson's disease 5.Significant discrepancies in the results of physical examination, vital functions and laboratory examination, which require further examination or treatment 6.Dependency disorders (e.g. benzodiazepine, alcohol) 7.Intake of cognitive impairing medication 8.Serious illness, that could prevent a participation throughout the entire observation period 9. Lives at a nursing home. 10. Pregnancy

Design outcomes

Primary

Measure	Time frame
Percentage of patients, whose diagnosis based on biomarker criteria differs from those, based on clinical diagnosis.	—

Secondary

Measure	Time frame
a. Percentage of patients, whose theraply plan changed based on the biomarker criteria diagnosis b. Modification of cognitive impairments within the patient group c. Modification of the patient's quality of life d. Modification of psychological and behavioural symptoms e. Modification of resource utilization/costs	—

Countries

Germany

Contacts

Public ContactSabine Thürk

alesco.concepts

studienbuero@alesco-concepts.de030 57703286

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026